385 related articles for article (PubMed ID: 27801901)
1. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
[TBL] [Abstract][Full Text] [Related]
3. High B7-H3 expression is linked to increased risk of prostate cancer progression.
Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
[TBL] [Abstract][Full Text] [Related]
4. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract][Full Text] [Related]
5. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
[TBL] [Abstract][Full Text] [Related]
6. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
8. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract][Full Text] [Related]
9. Clinical correlation of B7-H3 and B3GALT4 with the prognosis of colorectal cancer.
Zhang T; Wang F; Wu JY; Qiu ZC; Wang Y; Liu F; Ge XS; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2018 Aug; 24(31):3538-3546. PubMed ID: 30131660
[TBL] [Abstract][Full Text] [Related]
10. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
[TBL] [Abstract][Full Text] [Related]
11. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
[TBL] [Abstract][Full Text] [Related]
12. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.
Kang N; Xue H; Lin YY; Dong X; Classen A; Wu R; Jin Y; Lin D; Volik S; Ong C; Gleave M; Collins C; Wang Y
Cancer Gene Ther; 2023 Oct; 30(10):1382-1389. PubMed ID: 37452083
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
14. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
15. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
17. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival.
Murata T; Takayama K; Urano T; Fujimura T; Ashikari D; Obinata D; Horie-Inoue K; Takahashi S; Ouchi Y; Homma Y; Inoue S
Clin Cancer Res; 2012 Oct; 18(20):5617-27. PubMed ID: 22904106
[TBL] [Abstract][Full Text] [Related]
20. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
